Readily available biomarkers predict poor survival in metastatic pancreatic cancer

References

• Ballehaninna, U.K., and Chamberlain, R.S., 2012. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. Journal of gastrointestinal oncology, 3 (2), 105–119.
   PubMedGoogle Scholar
• Ballman, K.V., 2015. Biomarker: predictive or prognostic? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 (33), 3968–3971.
   PubMed Web of Science ®Google Scholar
• Collins, G.S., et al., 2015. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ (clinical research ed.), 350, g7594.
   PubMedGoogle Scholar
• Conroy, T., et al., 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England journal of medicine, 364 (19), 1817–1825.
   PubMed Web of Science ®Google Scholar
• Creemers, A., et al., 2017. Clinical value of ctDNA in upper-GI cancers: a systematic review and meta-analysis. Biochimica et biophysica acta. Reviews on cancer, 1868 (2), 394–403.
   PubMed Web of Science ®Google Scholar
• de Graaf, G., et al., 2018. The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. Cost effectiveness and resource allocation : C/E, 16, 23.
   PubMed Web of Science ®Google Scholar
• Ducreux, M., et al., ESMO Guidelines Committee, 2015. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the european society for medical oncology, 26(Suppl 5), v56–68.
   PubMed Web of Science ®Google Scholar
• Forrest, L.M., et al., 2004. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. British journal of cancer, 90 (9), 1704–1706.
   PubMed Web of Science ®Google Scholar
• Goldstein, D., et al., 2015. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of the National Cancer Institute, 107 (2), dju413.
   PubMedGoogle Scholar
• Haas, M., et al., 2013. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. Journal of cancer research and clinical oncology, 139 (4), 681–689.
   PubMed Web of Science ®Google Scholar
• Hang, J., et al., 2018. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer medicine, 7 (7), 2974–2984.
   Web of Science ®Google Scholar
• Imaoka, H., et al., 2016. Evaluation of modified Glasgow prognostic score for pancreatic cancer: a retrospective cohort study. Pancreas, 45 (2), 211–217.
   PubMed Web of Science ®Google Scholar
• Inoue, D., et al., 2015. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Japanese journal of clinical oncology, 45 (1), 61–66.
   PubMed Web of Science ®Google Scholar
• Ioannidis, J.P., 2010. Expectations, validity, and reality in omics. Journal of clinical epidemiology, 63 (9), 945–949.
   PubMed Web of Science ®Google Scholar
• Kruger, S., et al., 2018. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 29 (12), 2348–2355.
   PubMed Web of Science ®Google Scholar
• Liu, Z., et al., 2017. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Annals of surgical oncology, 24 (2), 561–568.
   PubMed Web of Science ®Google Scholar
• Mackay, T.M., et al., 2019. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: a population-based analysis. European journal of cancer, 106, 99–105.
   PubMed Web of Science ®Google Scholar
• Mackinnon, A., 2010. The use and reporting of multiple imputation in medical research – a review. Journal of internal medicine, 268 (6), 586–593.
   PubMed Web of Science ®Google Scholar
• McMillan, D.C., 2013. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer treatment reviews, 39 (5), 534–540.
   PubMed Web of Science ®Google Scholar
• McShane, L.M., et al., Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, 2005. REporting recommendations for tumour MARKer prognostic studies (REMARK). European journal of cancer (Oxford, England : 1990), 41 (12), 1690–1696.
   PubMed Web of Science ®Google Scholar
• Piciucchi, M., et al., 2017. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. International journal of molecular sciences, 18 (4), 730.
   PubMed Web of Science ®Google Scholar
• Sauerbrei, W., et al., 2018. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): an abridged explanation and elaboration. Journal of the National Cancer Institute, 110 (8), 803–811.
   PubMedGoogle Scholar
• Schafer, J.L., and Graham, J.W., 2002. Missing data: our view of the state of the art. Psychological methods, 7 (2), 147–177.
   PubMed Web of Science ®Google Scholar
• Sobin, L. H., Gospodarowicz, M. K., and Wittekind, C., 2009. International Union Against Cancer (UICC) – the TNM classification of malignant tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell.
   Google Scholar
• Strijker, M., et al., 2019. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. International journal of cancer, 146 (5), 1445–1456.
   PubMed Web of Science ®Google Scholar
• Tas, F., et al., 2014. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer chemotherapy and pharmacology, 73 (6), 1163–1171.
   PubMed Web of Science ®Google Scholar
• Ter Veer, E., et al., 2018. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet oncology, 19 (3), e151–e160.
   PubMed Web of Science ®Google Scholar
• van der Geest, L.G.M., et al., the Dutch Pancreatic Cancer Group, 2017. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer medicine, 6 (12), 2840–2849.
   PubMed Web of Science ®Google Scholar
• van der Sijde, F., et al., 2019. Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers (Basel), 11 (1), 93.
   Web of Science ®Google Scholar
• Vincent, A., et al., 2011. Pancreatic cancer. The lancet (London, England), 378 (9791), 607–620.
   PubMed Web of Science ®Google Scholar
• Von Hoff, D.D., et al., 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England journal of medicine, 369 (18), 1691–1703.
   PubMed Web of Science ®Google Scholar
• Yu, S.L., et al., 2017. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. Scientific reports, 7, 45194.
   PubMed Web of Science ®Google Scholar